Saxagliptin but Not Sitagliptin Inhibits CaMKII and PKC via DPP9 Inhibition in Cardiomyocytes

Saxagliptin but Not Sitagliptin Inhibits CaMKII and PKC via DPP9 Inhibition in Cardiomyocytes

Some oral anti-hyperglycemic drugs, including gliptins that inhibit dipeptidyl peptidase 4 (DPP4), have been linked to the increased risk of heart failure (HF) in type-2 diabetic patients. While the cardiovascular safety trial, TECOS, revealed no link between sitagliptin and the risk of HF, a substa...

Full description

Bibliographic Details
Main Authors: Chintan N. Koyani, Christopher Trummer, Niroj Shrestha, Susanne Scheruebel, Benjamin Bourgeois, Ioanna Plastira, Sandra Kickmaier, Harald Sourij, Peter P. Rainer, Tobias Madl, Wolfgang Sattler, Brigitte Pelzmann, Ernst Malle, Dirk von Lewinski
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-11-01
Series:Frontiers in Physiology
Subjects:
diabetes
heart failure
gliptins
Ca2+ transient
cardiac electrophysiology
Online Access:https://www.frontiersin.org/article/10.3389/fphys.2018.01622/full

Internet

https://www.frontiersin.org/article/10.3389/fphys.2018.01622/full

Similar Items